滚动资讯
IlluminaIs It Time To Reassess Illumina (ILMN) After Its 61.7% One Year Share Price Rebound - Yahoo FinanceThermo FisherWallace Advisory Group Reduces Stake in Thermo Fisher Scientific - National Today10x Genomics Blog10X Genomics Opens with 6.32% Gain, Outperforming S&P 500's 2.51% Increase - Markets MojoAgilentScaling Antibody-Drug Conjugate Characterization with Lab Automation - the-scientist.comAgilentMassachusetts Financial Services Co. MA Raises Stock Position in Agilent Technologies, Inc. $A - MarketBeatEndpoints NewsMore pharma dealmaking; FDA’s proposed budget; Takeda ends partnership; and moreThermo FisherIs It Too Late To Consider Thermo Fisher Scientific (TMO) After Recent Share Price Weakness? - Yahoo FinanceThermo FisherThermo Fisher expands global biobank leadership through collaboration with PRECISE-SG100K Singapore - BioSpectrum Asia10x Genomics BlogTXG (10x Genomics) Receipts from Customers - GuruFocusBioWorldSecond CRL for Replimune’s RP-1 for melanomaFierceBiotechFDA rejects Replimune’s melanoma prospect for second timeEndpoints NewsPlan for remade ACIP panel adds focus on vaccine safety, matching Kennedy’s push
Illumina 2026年4月11日

Is It Time To Reassess Illumina (ILMN) After Its 61.7% One Year Share Price Rebound - Yahoo Finance

Is It Time To Reassess Illumina (ILMN) After Its 61.7% One Year Share Price Rebound - Yahoo Finance

原文
暂时没有全文，请查看原始来源。

目录

59 全部